Smith Graham & Co Investment Advisors’s Elevance Health ELV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | $6.6M | Sell |
14,000
-1,426
| -9% | -$659K | 0.76% | 52 |
|
|
2023
Q3 | $6.72M | Sell |
15,426
-131
| -0.8% | -$59.4K | 0.84% | 39 |
|
|
2023
Q2 | $6.91M | Sell |
15,557
-155
| -1% | -$71.5K | 0.84% | 44 |
|
|
2023
Q1 | $7.22M | Sell |
15,712
-398
| -2% | -$189K | 0.88% | 40 |
|
|
2022
Q4 | $8.26M | Sell |
16,110
-1,090
| -6% | -$553K | 1.01% | 26 |
|
|
2022
Q3 | $7.81M | Sell |
17,200
-993
| -5% | -$475K | 1.04% | 24 |
|
|
2022
Q2 | $8.78M | Sell |
18,193
-475
| -3% | -$235K | 1.08% | 20 |
|
|
2022
Q1 | $9.17M | Buy |
18,668
+642
| +4% | +$293K | 0.95% | 30 |
|
|
2021
Q4 | $8.36M | Sell |
18,026
-262
| -1% | -$110K | 0.83% | 44 |
|
|
2021
Q3 | $6.82M | Sell |
18,288
-2,023
| -10% | -$769K | 0.69% | 67 |
|
|
2021
Q2 | $7.75M | Sell |
20,311
-3,105
| -13% | -$1.19M | 0.69% | 60 |
|
|
2021
Q1 | $8.4M | Sell |
23,416
-3,089
| -12% | -$993K | 0.68% | 60 |
|
|
2020
Q4 | $8.51M | Sell |
26,505
-2,472
| -9% | -$759K | 0.78% | 49 |
|
|
2020
Q3 | $7.78M | Sell |
28,977
-1,233
| -4% | -$332K | 0.89% | 35 |
|
|
2020
Q2 | $7.95M | Buy |
30,210
+111
| +0.4% | +$29.6K | 0.96% | 32 |
|
|
2020
Q1 | $6.83M | Buy |
30,099
+252
| +0.8% | +$68.7K | 1.07% | 25 |
|
|
2019
Q4 | $9.02M | Sell |
29,847
-780
| -3% | -$215K | 0.88% | 38 |
|
|
2019
Q3 | $7.35M | Buy |
30,627
+40
| +0.1% | +$11K | 0.78% | 55 |
|
|
2019
Q2 | $8.63M | Sell |
30,587
-1,300
| -4% | -$355K | 0.93% | 29 |
|
|
2019
Q1 | $9.15M | Sell |
31,887
-2,420
| -7% | -$700K | 1.01% | 19 |
|
|
2018
Q4 | $9.01M | Sell |
34,307
-5,470
| -14% | -$1.5M | 1.1% | 15 |
|
|
2018
Q3 | $10.9M | Sell |
39,777
-1,600
| -4% | -$415K | 1.03% | 21 |
|
|
2018
Q2 | $9.85M | Sell |
41,377
-830
| -2% | -$192K | 0.93% | 28 |
|
|
2018
Q1 | $9.27M | Sell |
42,207
-490
| -1% | -$115K | 0.89% | 33 |
|
|
2017
Q4 | $9.61M | Buy |
42,697
+7,550
| +21% | +$1.61M | 0.9% | 35 |
|
|
2017
Q3 | $6.67M | Sell |
35,147
-250
| -0.7% | -$47.6K | 0.7% | 65 |
|
|
2017
Q2 | $6.66M | Sell |
35,397
-350
| -1% | -$62.9K | 0.72% | 60 |
|
|
2017
Q1 | $5.91M | Sell |
35,747
-2,660
| -7% | -$423K | 0.63% | 72 |
|
|
2016
Q4 | $5.52M | Sell |
38,407
-3,150
| -8% | -$422K | 0.6% | 75 |
|
|
2016
Q3 | $5.21M | Sell |
41,557
-610
| -1% | -$78.8K | 0.66% | 66 |
|
|
2016
Q2 | $5.54M | Sell |
42,167
-280
| -0.7% | -$38.3K | 0.76% | 53 |
|
|
2016
Q1 | $5.9M | Buy |
42,447
+4,300
| +11% | +$575K | 0.77% | 55 |
|
|
2015
Q4 | $5.32M | Buy |
38,147
+1,240
| +3% | +$171K | 0.75% | 58 |
|
|
2015
Q3 | $5.17M | Buy |
36,907
+810
| +2% | +$122K | 0.75% | 56 |
|
|
2015
Q2 | $5.92M | Sell |
36,097
-320
| -0.9% | -$51.1K | 0.8% | 54 |
|
|
2015
Q1 | $5.62M | Sell |
36,417
-270
| -0.7% | -$38.4K | 0.76% | 58 |
|
|
2014
Q4 | $4.61M | Buy |
36,687
+590
| +2% | +$72.9K | 0.66% | 66 |
|
|
2014
Q3 | $4.32M | Buy |
36,097
+2,150
| +6% | +$247K | 0.64% | 68 |
|
|
2014
Q2 | $3.65M | Sell |
33,947
-370
| -1% | -$38.1K | 0.51% | 76 |
|
|
2014
Q1 | $3.42M | Sell |
34,317
-530
| -2% | -$47.9K | 0.49% | 79 |
|
|
2013
Q4 | $3.22M | Sell |
34,847
-12,760
| -27% | -$1.13M | 0.46% | 78 |
|
|
2013
Q3 | $3.98M | Sell |
47,607
-470
| -1% | -$40.3K | 0.58% | 75 |
|
|
2013
Q2 | $3.94M | Buy |
+48,077
| New | +$3.6M | 0.61% | 76 |
|
Other funds holding ELV
Smith Graham & Co Investment Advisors's ELV Position: Q4 2023 in Review
Smith Graham & Co Investment Advisors reduced its Elevance Health (ELV) stake by 9.2% in Q4 2023, selling an estimated $659K and leaving 14,000 shares worth $6.6M. The position accounts for 0.76% of the portfolio, ranked #52.
Smith Graham & Co Investment Advisors first reported a position in ELV in Q2 2013 and has held it in 43 quarters since. The position peaked at $10.9M in Q3 2018. 1,655 funds tracked by Wall St. Rank hold ELV as of Q4 2023.
- Smith Graham & Co Investment Advisors held 14,000 shares of Elevance Health worth $6.6M as of Q4 2023.
- Smith Graham & Co Investment Advisors sold 1,426 Elevance Health shares in Q4 2023, an estimated $659K.
- Elevance Health made up 0.76% of Smith Graham & Co Investment Advisors's portfolio in Q4 2023, its #52 holding.
- Smith Graham & Co Investment Advisors first reported a position in Elevance Health in Q2 2013 and has held it in 43 quarters since.
- Smith Graham & Co Investment Advisors's Elevance Health position peaked at $10.9M in Q3 2018.
- 1,655 funds tracked by Wall St. Rank held Elevance Health as of Q4 2023.
Based on Smith Graham & Co Investment Advisors's 13F filing for Q4 2023, filed 29 Jan 2024.